“Efficacy is critically important when treating C3G and IC-MPGN given the high risk of progression to kidney failure. As a disease-modifying therapy, EMPAVELI has the potential to make a life ...

Apellis and Sobi's Aspaveli application for C3G and IC-MPGN treatment validated by the EMA, addressing rare kidney diseases. Apellis Pharmaceuticals and Sobi announced that the European Medicines ...

"C3G and IC-MPGN are severe and life-threatening kidney conditions, often leading to kidney failure and requiring a kidney transplant or dialysis for life," said Lydia Abad-Franch MD, Head of R&D ...

(Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) for the treatment of C3 ...